Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance

Annika Herlemann, Huei Chung Huang, Ridwan Alam, Jeffery J. Tosoian, Hyung L. Kim, Eric A. Klein, Jeffry P. Simko, June M. Chan, Brian R. Lane, John W. Davis, Elai Davicioni, Felix Y. Feng, Peter McCue, Hyun Kim, Robert B. Den, Tarek A. Bismar, Peter R. Carroll, Matthew R. Cooperberg

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Background: We aimed to validate Decipher to predict adverse pathology (AP) at radical prostatectomy (RP) in men with National Comprehensive Cancer Network (NCCN) favorable-intermediate risk (F-IR) prostate cancer (PCa), and to better select F-IR candidates for active surveillance (AS). Methods: In all, 647 patients diagnosed with NCCN very low/low risk (VL/LR) or F-IR prostate cancer were identified from a multi-institutional PCa biopsy database; all underwent RP with complete postoperative clinicopathological information and Decipher genomic risk scores. The performance of all risk assessment tools was evaluated using logistic regression model for the endpoint of AP, defined as grade group 3−5, pT3b or higher, or lymph node invasion. Results: The median age was 61 years (interquartile range 56–66) for 220 patients with NCCN F-IR disease, 53% classified as low-risk by Cancer of the Prostate Risk Assessment (CAPRA 0−2) and 47% as intermediate-risk (CAPRA 3−5). Decipher classified 79%, 13% and 8% of men as low-, intermediate- and high-risk with 13%, 10%, and 41% rate of AP, respectively. Decipher was an independent predictor of AP with an odds ratio of 1.34 per 0.1 unit increased (p value = 0.002) and remained significant when adjusting by CAPRA. Notably, F-IR with Decipher low or intermediate score did not associate with significantly higher odds of AP compared to VL/LR. Conclusions: NCCN risk groups, including F-IR, are highly heterogeneous and should be replaced with multivariable risk-stratification. In particular, incorporating Decipher may be useful for safely expanding the use of AS in this patient population.

Original languageEnglish
Pages (from-to)136-143
Number of pages8
JournalProstate Cancer and Prostatic Diseases
Issue number1
StatePublished - Mar 1 2020


Dive into the research topics of 'Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance'. Together they form a unique fingerprint.

Cite this